Nachrichten zur Lisata Therapeutics Inc. Aktie

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company’s new research collaboration with Haystack...…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack’s MRD technology to evaluate the efficacy...…

Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational…

Complete enrollment achieved nearly six months ahead of plan…

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck talked with Proactive about encouraging preclinical results for their drug...…

Lisata Therapeutics Inc (NASDAQ:LSTA) has unveiled encouraging preclinical results for its drug candidate, certepetide, in intrahepatic cholangiocarcinoma,...…

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) announced it has completed enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.…

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech...…

Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its…

…

…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…

…

…

Achieves critical first step toward priority review voucher Achieves critical first step toward priority review voucher…

Earnings call: Lisata Therapeutics reports on clinical trials and finances…

…